西达本胺(Chidamide) - 药物靶点：HDACs_在研适应症：弥漫性大B细胞淋巴瘤，成人T细胞白血病/淋巴瘤，乳腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Tucidinostat、87CIC980Y0 (UNII code)、CS-02100055

+ [9]

靶点

HDACs

作用方式

抑制剂

作用机制

HDAC抑制剂(组蛋白去乙酰化酶家族抑制剂)、表观遗传学药物

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [7]

在研适应症

弥漫性大B细胞淋巴瘤成人T细胞白血病/淋巴瘤乳腺癌+ [23]

非在研适应症

晚期乳腺癌晚期宫颈癌难治性B细胞淋巴瘤+ [14]

原研机构

深圳微芯生物科技股份有限公司

在研机构

Bristol Myers Squibb Co.

Huyabio International LLC

Meiji Seika Pharma Co., Ltd.

+ [3]

非在研机构-

权益机构

华上生技医药股份有限公司

深圳微芯生物科技股份有限公司

Huyabio International LLC

+ [6]

最高研发阶段批准上市

首次获批日期

中国 (2014-12-23),

外周T细胞淋巴瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、突破性疗法 (中国)、附条件批准 (中国)、特殊审批 (中国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C22H19FN4O2

InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N

CAS号1616493-44-7

关联

267

项与西达本胺相关的临床试验

NCT06947967

/ Not yet recruiting临床3期

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)

A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype

开始日期2025-06-01

申办/合作机构

深圳微芯生物科技股份有限公司

NCT06951997

/ Not yet recruiting临床2期IIT

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chidamide, Albumin-bound Paclitaxel and Gemcitabine as First-line Treatment for Metastatic Pancreatic Cancer

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.

开始日期2025-05-15

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

NCT06570447

/ Recruiting临床2期IIT

An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

开始日期2025-05-15

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

100 项与西达本胺相关的临床结果

登录后查看更多信息

100 项与西达本胺相关的转化医学

登录后查看更多信息

100 项与西达本胺相关的专利（医药）

登录后查看更多信息

2,509

项与西达本胺相关的文献（医药）

2025-09-01·LEUKEMIA RESEARCH

HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells

Article

作者: Nakamura, Yuka ; Mitani, Kinuko ; Nakamura, Fumi ; Yamazaki, Ieharu ; Sasaki, Ko ; Imai, Yoichi

The RUNX1-MECOM fusion gene generated by the t(3;21)(q26;q22) translocation is a causative gene of acute megakaryoblastic leukemia, and the generated product performs various molecular functions by recruiting histone deacetylase (HDAC). We had previously established a mouse bone marrow transplantation model through the retroviral transduction of RUNX1-MECOM. This model demonstrated that RUNX1-MECOM-expressing cells developed acute megakaryoblastic leukemia and were serially transplantable. Gene expression analyses using quantitative RT-PCR arrays revealed that Angpt1 (Angiopoietin 1) and Tek transcripts were elevated in the leukemic cells. In this study, we confirmed the concomitant expression of Angpt1 and Tek proteins in the RUNX1-MECOM-expressing cells. When the primary leukemic cells were stimulated with exogenous Angpt1, endogenous Tek was phosphorylated, followed by the phosphorylation of downstream Akt. Angpt1 and Tek may form a circuit of an autocrine loop and enhance leukemia cell survival. Interestingly, the expression of Tek and Angpt1 was downregulated by HDAC inhibitors (HDACi), trichostatin A (TSA) and valproic acid (VPA). Therefore, HDACi may block the Angpt1 and Tek autocrine loop. Both TSA and VPA inhibited the growth of RUNX1-MECOM-expressing cells in vitro by inducing cell cycle arrest and apoptosis. Electron microscopic analysis further indicated that partial megakaryocytic differentiation was induced after HDACi treatment. Furthermore, intraperitoneal injection with VPA, but not TSA, extended the survival of the secondary transplanted mice. These data demonstrate the potential of HDACi as a promising targeted treatment for RUNX1-MECOM-type leukemia.

2025-08-01·SEMINARS IN CANCER BIOLOGY

HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury

Review

作者: Zhang, Hang ; Bates, Susan E ; To, Kenneth K W ; Tolu, Seda S ; Cho, William C ; Wang, Longling

Histone deacetylase inhibitors (HDACIs) are epigenetic drugs that regulate the acetylation status of histones and non-histone proteins, thereby leading to chromatin remodeling and transcriptional regulation of key apoptotic and cell cycle regulatory genes. There are currently five HDACIs clinically approved by the major regulatory authorities for treating hematological cancers, primarily as monotherapy. While HDACIs have been particularly effective in T-cell lymphomas, their clinical efficacies have not yet extended to solid tumors. The development of HDACIs continues, including for the treatment of a non-malignant conditions, with givinostat recently approved by the US FDA. However, the early development of HDACIs was limited by concerns about cardiotoxicity including QT interval prolongation. Yet, paradoxically, the latest research suggests some cardioprotective effect of HDACIs in ischemic heart disease or heart failure. This review presents the latest update about the cardiotoxicity of the clinically approved HDACIs. The mechanisms leading to HDACI-induced cardiotoxic adverse events and clinical strategies for their management are discussed. We will also deliberate the potential repurposing use of HDACIs and their HDAC isoform selectivity for treating ischemia-reperfusion cardiac muscle injury, cardiac hypertrophy, and fibrosis.

2025-07-01·BIOORGANIC CHEMISTRY

Design and synthesis of novel Hydroxamate and non-Hydroxamate HDAC inhibitors based on Chromone and Quinazolone scaffolds

Article

作者: Ashraf, Rosaline ; Abouzid, Khaled A M ; Soror, Sameh ; Ibrahim, Esraa ; Serya, Rabah A T ; Haffez, Hesham ; Adel, Mai

The development of selective histone deacetylase (HDAC) inhibitors represents an encouraging approach for cancer therapy. In this study, we report design, synthesis, and biological evaluation of hydroxamate, amidoxime, and carboxylic acid-based derivatives as novel HDAC inhibitors. The synthesized compounds were assessed for their inhibitory activity against multiple HDAC isoforms, particularly HDAC6, 7, and 8. Compounds 13, 16, 20, and 26 exhibited potent and selective inhibition of HDAC6. Compound 26 exhibited the most potent inhibitory activity against HDAC6, with an IC₅₀ value of 70 nM. Additionally, compounds 17 and 23 demonstrated significant broad-spectrum antiproliferative activity across various cancer cell lines compared to other tested derivatives. Furthermore, compounds 17 and 23 showed promising total pan-HDAC inhibitory activity. Subsequent biological studies revealed that compounds 13, 16, 17, 20, 23, and 26 induced a combination of early and late apoptosis along with necrosis. In silico studies, including molecular docking and ADME predictions, were also conducted. Collectively, these findings highlight the potential of these compounds as promising candidates for the development of a novel class of selective HDAC6 inhibitors in the future.

262

项与西达本胺相关的新闻（医药）

2025-07-01

·cerenoscientific.com

Cereno Scientific is included in Nasdaq’s First North 25™ Index

01 Jul 2025 06:00 Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company is added to the First North 25™ Index (FN25 Index). The Index gathers a selection of the largest and most traded securities on the Nasdaq Nordic First North Growth Markets. The inclusion is effective at market open on Tuesday, July 1, 2025. "Being included in the First North 25 Index is a proud milestone for Cereno Scientific and a reflection of the progress we have made in building a strong and credible biotech company. It also represents the trust and long-term belief placed in us by our shareholders, who continue to support our mission to develop pioneering treatments for patients with rare cardiovascular and pulmonary diseases. We remain focused on delivering scientific, clinical, and strategic value for patients and shareholders as we move forward,” said Sten R. Sörensen, CEO at Cereno Scientific. The First North 25 Index measures the performance of a selection of the largest and most traded securities listed on the Nasdaq Nordic First North Growth Markets (First North Denmark, First North Finland, First North Iceland and First North Sweden). Further information is available on https://indexes.nasdaqomx.com/Index/Overview/FN25 For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床1期临床2期

2025-06-30

·深圳微芯生物科技股份有限公司

微芯生物每月新闻简讯（6月刊）

精选微芯生物要闻，把握近期公司热点，敬请关注微芯生物每月新闻简讯。01西达本胺19项最新成果入选EHA 20252025年欧洲血液学协会年会（EHA 2025）上，西达本胺（爱谱沙®）在T细胞淋巴瘤、B细胞淋巴瘤、急性髓系白血病、急性淋巴细胞白血病等治疗领域的19项最新成果以壁报及在线摘要形式亮相，展示血液肿瘤多领域治疗中的广阔应用前景和显著疗效。本届EHA年会，4家科创板创新药企近60项临床研究成果亮相，微芯生物成果占三分之一。02HDAC新进展！西达本胺领衔的CAP三联方案为实体瘤治疗提供新策略 6 月 2 日，中山大学肿瘤防治中心徐瑞华教授团队在肿瘤学权威期刊《Cancer Discovery》杂志发表题为《Vascular Normalization Augments the Anti-tumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors》的研究论文。研究发现，组蛋白去乙酰化酶抑制剂西达本胺可增强CD8阳性T细胞效应分子的染色质可及性，进而提升其抗肿瘤能力。同时，免疫治疗联合抗血管生成治疗可逆转血管异常，显著增强CD8阳性T细胞的浸润和功能，提出HDACi+抗血管生成治疗+免疫治疗的CAP三联治疗方案，为实体瘤治疗提供新策略。03微芯生物董事长兼总经理鲁先平博士出席首届国际医药健康产业创新大会6月5日-7日，“论道永安湖——首届国际医药健康产业创新大会”在成都天府国际生物城成功举办。大会以“汇聚生态之力・点亮生命之光”为主题，围绕医药健康产业全链条创新的核心议题，邀请140余位生物医药领军企业代表、学术界专家分享精彩报告。微芯生物董事长兼总经理鲁先平博士出席大会并做《新形势下进一步完善我国医药创新政策的几点思考》主题报告。04微芯生物出席中国医药创新促进会第十九次会员大会暨理事会6月18日，中国医药创新促进会第十九次会员大会暨第十二届理事会第一次会议在北京隆重召开。微芯生物作为理事单位出席本次大会，认真履行会员职责，参与审议并表决通过了包括章程修订、会费管理办法等多项重要议案。会议选举产生了新一届理事会，微芯生物董事长兼总经理鲁先平博士当选为中国医药创新促进会第十二届理事会理事。05西达本胺荣获中国生物医药卓越成就奖6月27日，美华药携生物医药科技大会在苏州举办，大会当日举行了“中国生物医药创新15年卓越成就奖”等颁奖仪式。经“CBA-China 中国年会”大会组委会联合药渡数据的评选，微芯生物西达本胺荣获“中国医药创新先锋奖”。06双百强！微芯生物荣登中国药品研发实力总榜及化药百强榜单6月20日，由药智网、中新社国际传播集团、《中国药业》杂志联合主办的“2025 PDI 医药研发·创新大会暨中国药品研发百强榜发布会”盛大开幕，《2025中国药品研发实力排行榜》系列榜单正式发布。微芯生物荣登《2025中国药品研发综合实力排行榜》及《2025中国化药研发实力排行榜》。07西格列他钠亮相鄂苏内分泌年会2025年6月，西格列他钠（双洛平®）相继亮相湖北省医学会内分泌学分会学术年会及2025年江苏省医学会第十七次内分泌学分会年会。微芯生物通过专题会和学术展台，重点展示西格列他钠在治疗2型糖尿病（合并脂肪肝）患者中的“降糖调脂、利肝安心”独特优势，为临床医生提供全新治疗选择。08微芯生物亮相全球BIO大会，加速国际化布局6月16日-19日，国际生物技术大会暨展览会于波士顿举行。作为全球最具影响力的生物医药行业盛会，本届BIO大会汇聚了来自全球的制药巨头、生物科技领军企业及顶尖投资机构。微芯生物（美国）公司总经理Stephen Xue及微芯生物商务拓展负责人张佳文出席大会，重点展示了微芯生物在肿瘤、代谢与自免疾病领域的创新研发管线，通过与国际合作伙伴的深入交流，积极寻求在临床开发、商业化拓展及资本合作等领域的战略机遇，加速推动微芯生物创新疗法走向全球市场。09贡献巾帼智慧与力量！6月25日，深圳市“三新”领域妇联组织建设现场会暨坪山区生物医药产业链妇联成立大会隆重举行并成立“深姐姐”宣讲团。深圳微芯药业总经理刘馨出席大会并受聘为坪山区生物医药产业链妇联副主席，与来自研发、生产、管理、销售等环节的优秀女性代表共聚，为提升坪山区生物医药产业国际竞争力贡献智慧与力量，推动产业发展。10微芯生物参与“博览英才港澳校企活动”近日，南山区人力资源局主办的“博览英才港澳校企活动”。微芯生物早期研发中心周游博士代表参加，在澳门大学、澳门科技大学等高校展示了公司的研发成果，与校方教授深入探讨了潜在的合作方向，并拓展人才引进渠道。11微芯生物2025公益行动再赴良洞希望小学6月13日，微芯生物集团总部联合子公司深圳微芯药业再度走进遂川县汤湖镇良洞希望小学，捐赠体育器材、打印机、文具及图书等物资，助力构建优质学习环境，赋能青少年全面发展。微芯生物践行“创新科技服务社会”理念，持续深耕教育公益，以科技之力传递温暖。12成都微芯药业“学习强企”系列培训，筑牢发展根基2025年6月，成都微芯药业围绕安全生产、技术规范、财务管理、法律风险及知识产权布局五大领域开展系列培训。多部门协同发力，强化管理责任，提升财务管理能力，规范验证流程，筑牢合规与创新防线，以训促学夯实人才根基，推动企业高质量发展。往期推荐当爸的年纪，要小心一件事瘦不下来？可能是“胰岛素抵抗”不管胖哪里，都不要胖这里！微芯生物倡导高质量体重管理

免疫疗法微生物疗法高管变更

2025-06-30

·cerenoscientific.com

Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the top-line results of CS014’s Phase I trial will be announced mid-July 2025. The previously communicated timeline was June 2025. The Phase I trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. "The first-in-human Phase I trial of CS014 was successfully conducted and concluded in April. Since then, the contract research organization (CRO) has followed standard procedures in collating, verifying and analyzing data to prepare the study report. We look very much forward to the top-line results in mid-July and the next stage of the development program for CS014 to start this fall,” said Sten R. Sörensen, CEO at Cereno Scientific. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action. Being an epigenetic modulator, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target indication is idiopathic pulmonary fibrosis (IPF). The Phase I trial evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The trial was conducted in two parts: part one explored safety, tolerability and PK of single ascending oral doses (SAD) of CS014; part two explored safety, tolerability, PK, and PD following multiple ascending doses (MAD) of CS014, dosed for seven days. In total, 48 subjects were included in the trial, 30 in the SAD and 18 in the MAD part. The trial was conducted in Sweden. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床1期临床2期临床结果

100 项与西达本胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	西达本胺	L01XX	DB06334

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	中国	深圳微芯生物科技股份有限公司	2024-04-24
成人T细胞白血病/淋巴瘤	日本	Meiji Seika Pharma Co., Ltd.	2021-06-23
乳腺癌	中国	深圳微芯生物科技股份有限公司	2019-11-20
外周T细胞淋巴瘤	中国	深圳微芯生物科技股份有限公司	2014-12-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除的大肠癌	临床3期	中国	深圳微芯生物科技股份有限公司	2024-11-27
转移性微卫星稳定结直肠癌	临床3期	中国	中山大学	2023-03-01
微卫星稳定型结直肠癌	临床3期	中国	中山大学	2023-03-01
脑转移瘤	临床3期	美国	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	美国	Bristol Myers Squibb Co.	2021-08-12
脑转移瘤	临床3期	日本	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	日本	Bristol Myers Squibb Co.	2021-08-12
脑转移瘤	临床3期	澳大利亚	Bristol Myers Squibb Co.	2021-08-12
脑转移瘤	临床3期	澳大利亚	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	奥地利	Bristol Myers Squibb Co.	2021-08-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04562311 (ASCO2025) 人工标引	临床2期	晚期尿路上皮癌	45	Chidamide + tislelizumab	繭獵齋鏇鏇蓋襯膚壓獵(構簾製願遞願鏇鑰淵積) = 憲鏇壓壓糧衊廠鏇艱鑰鬱製獵糧製簾鬱廠鬱遞 (齋網艱艱夢鏇積壓願壓, 29.6 ~ 60.0) 更多	积极	2025-05-30
NCT04994210 (SCENT-2, ASCO2025) 人工标引	临床2期	结外NK-T细胞淋巴瘤 \| T细胞淋巴瘤一线	47	Sintilimab + Chidamide (part A)	選壓壓鹹蓋構襯遞鏇鏇(選鬱築獵窪觸襯築範膚) = 壓醖鹹鑰鬱顧顧獵鹽鹹網餘憲壓獵築顧窪廠製 (鹽網顧鏇醖顧選觸廠憲 ) 更多	积极	2025-05-30
NCT04994210 (SCENT-2, ASCO2025) 人工标引	临床2期	结外NK-T细胞淋巴瘤 \| T细胞淋巴瘤一线	47	Sintilimab + Chidamide + P-GemOx (part A+part B)	選壓壓鹹蓋構襯遞鏇鏇(選鬱築獵窪觸襯築範膚) = 觸艱繭構廠糧醖鹹膚廠網餘憲壓獵築顧窪廠製 (鹽網顧鏇醖顧選觸廠憲 ) 更多	积极	2025-05-30
ChiCTR2400080783 (B-Enefits/SCOG-B001, ASCO2025) 人工标引	临床2期	胆道癌一线	35	Envafolimab + Chidamide + GEMOX	網築夢獵鹹餘鏇糧膚憲(齋鹽製鑰壓願觸簾蓋鑰) = 醖觸齋選窪淵憲憲簾蓋網觸鑰衊鏇齋齋壓艱餘 (願糧齋選簾鏇醖繭鹽構 ) 更多	积极	2025-05-30
NCT05586841 (ASCO2025) 人工标引	临床1期	HR阳性/HER2阴性乳腺癌 HER2 Negative \| Hormone Receptor Positive	22	dalpiciclib + chidamide	簾廠醖蓋觸醖餘顧遞獵(築醖鹽齋繭選遞顧衊廠) = the MTD was established as Group C (dalpiciclib 100 mg/d, chidamide 25 mg BIW). 選製簾窪遞鏇餘憲衊鹹 (選鏇觸窪選艱蓋積積醖 )	积极	2025-05-30
NCT05586841 (ASCO2025) 人工标引	临床1期	HR阳性/HER2阴性乳腺癌 HER2 Negative \| Hormone Receptor Positive	22	dalpicicldalpiciclibchidamide (Group C: dalpiciclib 100 mg/d, chidamide 25 mg BIW)		积极	2025-05-30
NCT06584227 (ADEPT, ASCO2025) 人工标引	临床2期	胰腺癌一线	13	Adebrelimab + Chidamide + Gemcitabine + S-1	簾餘願網選膚範壓鏇膚(餘艱願構廠蓋鑰餘顧網) = 簾簾鹹鏇鹽構蓋憲鬱衊觸襯淵窪簾範繭鹽餘襯 (淵淵構鏇選簾製憲廠顧, 7.0–13.3) 更多	积极	2025-05-30
NCT04025931 (ASCO2025) 人工标引	临床2期	软组织肉瘤	69	Chidamide + toripalimab	築蓋鹹鹹選膚廠鬱淵餘(艱糧艱鬱淵構願鑰鬱淵) = 鏇積範構願獵築窪窪壓繭製遞憲醖鑰積鏇壓鑰 (齋製顧壓鹽鹹網製憲網 ) 更多	积极	2025-05-30
PF1008 (EHA2025)	N/A	T细胞淋巴瘤 CD7+	-	Chidamide	鹹齋積壓顧衊鹹蓋願艱(鹹網積鹽鑰鏇繭網襯艱) = 製築願壓醖蓋製餘網壓廠網襯醖鬱築選選膚廠 (蓋淵蓋鏇廠鏇鬱築鏇憲 ) 更多	-	2025-05-14
PB2330 (EHA2025)	N/A	前体B细胞急性淋巴细胞白血病 IKAROS \| TCL1A	-	CX-4945 + CHI	蓋廠蓋夢網繭淵網鏇蓋(觸鑰網窪選蓋製壓鹽夢) = 淵衊繭餘鏇窪醖遞糧鹽壓製構齋遞範壓鏇顧觸 (糧蓋鹹餘獵壓淵網衊積 ) 更多	-	2025-05-14
PB2357 (EHA2025)	N/A	前体T淋巴细胞白血病淋巴瘤 \| 淋巴母细胞淋巴瘤维持	75	Chidamide maintenance therapy	壓鑰鹽鹽衊網膚積鏇鬱(鹽衊鹽廠壓艱夢憲壓糧) = aGVHD occurred in 10 patients in the Chidamide group and 14 in the non-Chidamide group 壓積積糧襯淵膚餘觸醖 (衊壓範淵製壓廠構顧淵 ) 更多	积极	2025-05-14
PB2357 (EHA2025)	N/A	前体T淋巴细胞白血病淋巴瘤 \| 淋巴母细胞淋巴瘤维持	75	No maintenance therapy or non-Chidamide therapy		积极	2025-05-14
NCT05527912 (Smart Start trial, EHA2025)	临床2期	弥漫性大B细胞淋巴瘤 MYD88 \| PIM1 \| SOCS1 ... 更多	45	Zanubrutinib	構鬱構構獵築夢鏇夢衊(積餘簾鑰顧願製醖膚遞) = 壓淵廠蓋構鏇艱淵簾選構鑰齋獵齋選積顧願淵 (網製製繭齋網憲壓網願 ) 更多	积极	2025-05-14